Nanobac Pharmaceuticals, Inc.  

(Public, OTCMKTS:NNBP)   Watch this stock  
Find more results for Edward Stanton
0.00000 (0.00%)
Nov 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.00
Open 0.00
Vol / Avg. 30,200.00/624,426.00
Mkt cap 24,950.00
P/E     -
Div/yield     -
EPS -0.03
Shares 249.51M
Beta     -
Inst. own 0%

Key stats and ratios

Q4 (Dec '07) 2007
Net profit margin -23340.00% -36527.78%
Operating margin -22820.00% -35966.67%
EBITD margin - -24744.45%
Return on average assets -64.29% -87.40%
Return on average equity - -
Employees 1 -
CDP Score - -


5025 West Lemon Street
TAMPA, FL 33609
United States - Map

Website links


Nanobac Pharmaceuticals, Incorporated (Nanobac) is a research-based, bio-lifescience company. The Company is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.

Officers and directors

John D. Stanton Chairman of the Board, Chief Executive Officer, Chief Financial Officer
Age: 62
Alexander H. Edwards III Director
Age: 46
Benedict S. Maniscalco M.D. Director
Age: 71
Stephen Rechtschaffen Director
Age: 63